Home › Companies › FHTX

Foghorn Therapeutics

FHTX Lead: Phase 1 1 Biotech Distilled article ↓

Oncology Small Molecule

Most recent annual filing: 2026-03-11

Pipeline (1 active programs)

FHD-909

Small Molecule Target: SMARCA2

Non-Small Cell Lung Cancer Phase 1 oral Eli Lilly and Company

Technology platforms

Gene Traffic Control · Eli Lilly and Company

Proprietary platform providing integrated mechanistic understanding of the chromatin regulatory system; enables target identification, validation, and drugging via enzyme inhibitors, protein degraders, and transcription factor disruptors; primary focus in oncology with potential in immunology, inflammation, virology, and neurology

Targets: SMARCA2, CBP, EP300, ARID1B

Biotech Distilled coverage (1)

2026-07-08 Foghorn Therapeutics (FHTX) — Scientific Deep Dive for FHD-909 and the Chromatin Degrader Pipeline

Articles open on Substack. Some deep dives are subscriber-only.